Introduction: Onychomycosis is one of the most common nail diseases. Fingernail onychomycosis is significantly less frequent than toenail onychomycosis and it is often misdiagnosed due to its subtle clinical presentations. Objectives: We sought to analyze the clinical and onychoscopic features of culture-proven cases of fingernail onychomycosis in adult and pediatric patients. Methods: Medical records of 120 patients with onychomycosis limited to the fingernails were collected and analyzed across several dermatological centers (Italy, Switzerland, Spain, Greece, Brazil, India, Morocco, Tunisia). Data collected included age, sex, affected hand, affected fingernails, isolated fungal microorganism, clinical, and onychoscopic signs. Results: A total of 341 fingernails were analyzed. The most commonly affected hand was the right one ,and the most frequently affected digits were the second and third. The mean number of affected digits per patient was 2.84. Cultures identified Trichophyton rubrum in 54 cases, T. mentagrophytes var. interdigitalis in 20 cases, Aspergillus spp. in 8 cases, Candida spp. in 31 cases, and various other fungi in the remaining cases. Major clinical and onychoscopic features observed included onycholysis, subungual hyperkeratosis, leukonychia, chromonychia and absence of the cuticles. On the basis of all findings, 4 main types of fingernail onychomycosis were identified. Conclusions: Fingernail onychomycosis presents with distinct clinical and onychoscopy characteristics that can overlap with other nail conditions. Dermoscopy enhances diagnostic accuracy, but mycological confirmation is mandatory for a definitive diagnosis.

Background: There are few studies, mainly case reports, on the involvement of the nail unit in autoimmune bullous disorders. Summary: Nail involvement in autoimmune bullous disorders is a significant clinical phenomenon, marked by a range of manifestations, most often not presenting with blisters like on the skin but rather with alterations of the nail unit such as paronychia, onychomadesis, or onycholysis. This involvement is particularly notable due to the unique immunological features of the nail unit, including the expression of various antigens and the presence of Langerhans cells. Conditions like pemphigus vulgaris, bullous pemphigoid, epidermolysis bullosa acquisita, linear IgA disease, and bullous systemic lupus erythematosus can lead to nail abnormalities. The prevalence of nail manifestations varies according to the disorder, and diagnosis often relies on histopathological and immunofluorescence testing. Nail involvement correlates with disease severity and duration, sometimes serving as a herald sign. Further research is needed to guide therapeutic approaches for nail involvement in autoimmune bullous diseases. Key Messages: Nail involvement in autoimmune bullous nail disorders may be confusing as there are almost never bullae. One should keep the diagnosis in mind when facing an atypical paronychia.

Background: Malignant epithelial nail unit tumors pose significant diagnostic and therapeutic challenges due to their clinical presentation often mimicking benign conditions and due to the need to preserve as much nail unit function as possible during surgery. Early detection is crucial, even if none of these tumors represent a life-threatening disease. Objectives: This review focus on squamous cell carcinoma, verrucous carcinoma, eccrine porocarcinoma, onychocytic carcinoma, basal cell carcinoma, malignant onychopapilloma, malignant onycholemmal cyst and onycholemmal carcinoma. Methods: Existing literature on the aforementioned tumors has been revised and synthesized. Results: Clinical presentation, pathology, diagnostic procedures, risk factors and the challenges associated with surgical management have been described in detail. Conclusions: Malignant epithelial tumors of the nail unit require careful evaluation and management due to their complex presentation. Early detection and an informed surgical approach are essential to improve patient outcomes and minimize complications.

Purpose Psoriasis, Psoriatic Arthritis and Nail psoriasis are chronic diseases that share a common underlying etiology of immunity dysregulation, enhanced activation of inflammatory pathways and remitting-relapsing course. Although nails represent a small percentage of the body surface involvement of this site can lead to impaired quality of life, severe discomfort and even result in permanent disability. Current therapeutic options for nail psoriasis include a variety of topical and systemic treatments although they are often reported as unsatisfactory from patients either due to their poor effectiveness or disturbing side effects. Recently small molecule drugs such as the PDE4 inhibitors were introduced in clinical practice and specifically apremilast has shown to be an effective new treatment option for psoriasis and psoriatic arthritis. Considering either the specific mechanism of action of apremilast, we performed a real-life observational study of 24 weeks assessing apremilast role in nail psoriasis. Matherials and methods Patients received apremilast 30mg bid, orally. Safety and efficacy were assessed at weeks 0, 4, 8, 12 and 24 using Dermatologic Life Quality Index (DLQI) and Nail Area Psoriasis Severity Index (NAPSI). At T0 we took a nail sample to investigate the presence of onychomycosis. Culture tests were performed in all the patients to search for fungi. Results We recruited a total of 15 patients with nail psoriasis. The analysis of variance (one-way ANOVA) showed the following results: DLQI (F.15.7; p-value < .00001) and NAPSI (F.9.4; p-value < .00001). Three patients (20%) presented also onychomycoses at the beginning of the treatment. Conclusions Apremilast showed fast and sustained improvement of nail psoriasis over time and a complete resolution of life quality impairment due to the disease.

Introduction: Psoriasis (PsO), a chronic inflammatory, multisystemic, and multifactorial disease can cause endothelial dysfunction, artery calcification, and atherosclerotic disease. A higher incidence of vascular occlusive events has been observed in psoriatic patients compared to healthy controls, and multiple studies confirm the association between moderate-severe PsO and atherosclerosis, coronary artery calcification, and higher cardiovascular risk. Objective: We sought to analyze atherosclerotic disease prevalence in epiaortic vessels of psoriatic and non-psoriatic patients to understand if PsO could represent an independent risk factor predisposing to atherosclerotic disease. Methods: We evaluated 47 psoriatic patients without cardiovascular risk factors with color Doppler ultrasound (CDUS). If atheromatous plaques were detected, a computed tomography angiography (CTA) was performed. We evaluated 47 non-psoriatic patients without cardiovascular risk factors with CDUS. Atherosclerosis prevalence in both groups were statistically analyzed. CDUS performance was compared to CTA. Results: In the psoriatic group (mean age 50.9 years), 6 had atheromatous plaques and 12 had an intima-media thickness (IMT) > 1 mm (overall prevalence of atherosclerotic disease: 38.2%). All plaques detected with CDUS were confirmed at CTA. In the control group (mean age 51.3 years), CDUS revealed atheromatous plaques in 4 patients and IMT > 1 mm in 4 ones (overall prevalence of 17%). The difference of atherosclerotic disease prevalence between the groups was statistically significant (P < 0.05). Conclusion: Our results highlight that PsO could be considered a predisposing factor for atherosclerotic disease development in epiaortic vessels, as it causes an increased IMT, that is also considered an independent cardiovascular risk factor.

Introduction: Tinea capitis (TC) is a superficial fungal infection affecting the scalp. The existence of asymptomatic carriers (ACs) could represent a potential reservoir responsible of (re)contamination and failure of treatment. No prospective studies on ACs in household contacts of TC patients in Europe have been published to date. Objectives: The aim of this study was to assess the prevalence of ACs in a cohort of household contacts of children who were diagnosed with TC in the metropolitan area of Bruxelles, Belgium. Methods: This prospective observational study was conducted from October 2015 to April 2016 at the Dermatology Department of the University Hospitals Brugmann, Saint-Pierre, Queen Fabiola Children Hospital. Results: Ninety-nine cases of TC from 95 different family circles were included. The main infectious agent identified was Microsporum audouinii in 53 cases. The mean age of TC patients was 5.8 years. Male/female ratio was 2.8. Eighty-one household contacts of TC patients were enrolled in the study. Two cases of ACs (5%) were identified. Conclusions: M. audouinii was the most common pathogen identified. The prevalence of ACs we report is on average higher compared to other European large cities. Larger prospective studies including all close contacts of affected patients are required in order to establish guidelines regarding identification and management of ACs.

BACKGROUND: The efficacy and safety of certolizumab pegol over 52 weeks was compared in two groups of patients: Group 1 comprised patients naive to biologic treatments; Group 2 comprised patients previously treated with one or more antitumor necrosis factor (TNF)-alpha and/or anti-interleukin (IL) agents. METHODS: We reported results in 50 patients affected by both mild psoriasis (PsO) and psoriatic arthritis (PsA). Primary endpoint was a reduction from baseline at week 52 of Disease Activity Score (DAS44-ESR) in both groups of patients. Secondary endpoints were a reduction from baseline at week 52 of Psoriasis Area Severity Index (PASI), Visual Analog Scale for Pain (PAIN VAS), ESR, CRP, and Dermatology Life Quality Index (DLQI). RESULTS: We observed a statistically significant improvement of both cutaneous and rheumatic disease in all patients, with a consistent reduction of DAS44-ESR, PASI, and PAIN VAS from baseline to week 52. DAS44-ESR decreased from 3.9 at BL to 1.5 at W52 (Group 1), and from 3.8 to 1.7 at W52 (Group 2). Mean PASI Score decreased from 3.2 at baseline (BL) to 0.4 at W52 (Group 1), and from 5.4 to 0.7 at W52 (Group 2). Mean PAIN-VAS decreased from a value of 73.5 at BL to 2.5 at W52 (Group 1), and from a value of 62.4 at BL to 9.2 at W52 (Group 2). We also found a reduction in ESR, CRP and DLQI values for each time point. CONCLUSIONS: Our results confirm that CZP can be administered safely and effectively to treat both psoriasis and psoriatic arthritis irrespective of previous treatments with biologic agents.

Main subtypes of cutaneous lupus erythematosus are represented by acute, subacute cutaneous, intermittent and chronic cutaneous lupus erythematosus. Discoid lupus erythematosus represents the most common phenotype of chronic cutaneous lupus erythematosus. The spectrum of clinical manifestations mirrors that of several and distinct histopathological features. Such variability among different CLE subtypes is also observed at dermoscopy. Dermoscopy is nowadays considered an additional valuable method for skin lesions assessment in general dermatology, following and completing the well-known clinical diagnostic steps, such as medical history and clinical examination. In vivo reflectance confocal microscopy (RCM) is a non-invasive imaging tool able to assess the epidermis and upper dermis producing high resolution (horizontal ∼1.25 μm, vertical ∼5 μm), en face tissue sections used for melanocytic and inflammatory evaluation. In this study, we reported dermoscopic and RCM features about 9 patients affected by subacute and chronic lupus erythematosus retrospectively analyzed.

Background: female androgenetic alopecia (FAGA) is a common cause of non-scarring alopecia in women, affecting approximately 40% of women by age 50, bearing a significant psychosocial burden on affected patients. Platelet-rich plasma (PRP) has been widely investigated as a potential effective treatment for several dermatological conditions, including male androgenetic alopecia (MAGA). However, few studies have been conducted focusing on the use of PRP in FAGA. The aim of this review was to identify reports that investigated the use of PRP for the treatment of FAGA. Methods: Electronic databases of MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception to September 2020 have been searched using different combinations of the following terms: "androgenetic alopecia," "FAGA," "female pattern hair loss," "platelet-rich fibrin," "platelet-rich plasma," and "PRP". Results and conclusions: Eight (n = 8) clinical studies consistent with our research were identified. A total of 197 subjects has been enrolled in the included studies. All of them were adult female patients (mean age: 38.9) affected by female pattern hair loss. PRP is a well-tolerated procedure which showed promising results in males-only and mixed populations of AGA patients. PRP showed to produce high levels of satisfaction and improvement in the quality of life in patients affected by FAGA. In the light of this evidence, PRP may be proposed in patients who did not respond or did not tolerate topical minoxidil, as well as in combination with topical and oral treatments.

Background Onychomycosis affects 5.5% of the general population and represents up to 50% of all nail diseases. Diagnosis and pathogen identification are essential in order to plan an adequate treatment. Many diagnostic techniques are available, and however, no solid data regarding comparison between different techniques over a large number of specimens are available to date. Objectives To compare sensitivity and specificity of direct examination, histopathology and fungal culture in our referral mycology laboratory. Methods Nail specimens received at the cutaneous pathology and mycology laboratory of the University Hospital Saint-Pierre (Brussels, Belgium) between 1 January and 15 May 2018 were retrospectively analysed. All specimens were submitted to direct examination and culture. In cases of adequate specimen size, histopathology was performed. Fungal culture was considered the gold standard for diagnosis. Results A total of 2245 nail samples were included in the study. Onychomycosis was diagnosed in 1266 specimens. Sensitivity and positive predictive value were found to be higher for direct examination compared to histopathology, while sensitivity of direct examination was found to be lower. Combined approach with all the three techniques showed the highest rate of positivity, followed by the association of direct examination and histopathology. Conclusions To our knowledge, this study included the largest number of nail specimens to date, allowing a comparison between direct examination, culture and histopathology. Direct examination showed to be the most performing technique in routine practice. Histopathology represents the most effective option in cases where both specimen size and laboratory resources are adequate. Our paper adds to the literature the 'real-life' experience of the mycology laboratory of a referral centre for nail diseases.

We present the results on retrospective analysis about the efficacy of Certolizumab pegol (CZP), an antitumor necrosis factor‐alpha agent, as monotherapy on skin psoriasis (PsO) in patients affect both by psoriatic arthritis (PsA) and mild‐severe PsO. To date, the CZP is authorized for the treatment of PsA, PsO beyond that rheumatoid arthritis, axial spondyloarthritis/ankylosing spondylitis, and Crohn's. Assessments included an evaluation of the Psoriasis Area and Severity Index (PASI). Twelve patients (9M and 3F mean age 57.8 ± 8 years) were enrolled in our study. Nine patients had been previously treated with others biologic agents, three patients were naïve. Clinical and laboratory evaluations including PASI, erythrosedimentation rate, and C‐reactive protein were performed at baseline (BL), at Week 12 (W12), Week 24 (W24), and Week 52 (W52) of treatment. Although the combination between methotrexate and CZP is allowed, we included, in our study, patients treated only with CZP. In such a way as to be as specific as possible, topical corticosteroids, vitamin D derivatives, retinoid creams, anthralin derivatives as well as p‐UVA or UV‐B have been forbidden to enrolled patients. With the same purpose, all the patients used the identical moisturizing cream two times a day. Mean PASI score decreased from 18 (BL) to 0 (W52) as follows: 18 at BL, 4 at W12, 0 at W24, and 0 at W52. Severe adverse events were not reported. Safety evaluations were performed every 3 months: liver and renal functions were monitored in all patients during the treatment, and no patient presented abnormal values. To the best of our knowledge, this is the first report that highlights the efficacy of CZP as monotherapy in psoriasis with mild to severe cutaneous involvement. Although to date the drug is authorized only for PsA, our results demonstrate that CZP is safe and effective on both cutaneous and joint components representing, therefore, an effective option in the treatment of cutaneous symptoms of PsO. Limitations of our study are presented by the relatively short observation time (W52) and by numeric small study group. Long‐term data with a larger number of enrolled patients are necessary in order to confirm our preliminary observations.

Journal of the European Academy of Dermatology and VenereologyVolume 34, Issue 11 p. e724-e726 Letter to the Editor Aplasia cutis: clinical, dermoscopic findings and management in 45 children M.A. Chessa, M.A. Chessa Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ItalySearch for more papers by this authorF. Filippi, Corresponding Author F. Filippi federicafilippi8@gmail.com orcid.org/0000-0001-8173-4257 Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy Correspondence: F. Filippi. E-mail: federicafilippi8@gmail.comSearch for more papers by this authorA. Patrizi, A. Patrizi orcid.org/0000-0002-8398-0483 Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ItalySearch for more papers by this authorL. Vollono, L. Vollono orcid.org/0000-0001-8858-9531 Dermatology Unit, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, ItalySearch for more papers by this authorA. Sechi, A. Sechi Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ItalySearch for more papers by this authorM. D'Ercole, M. D'Ercole Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ItalySearch for more papers by this authorM. Leuzzi, M. Leuzzi orcid.org/0000-0002-6333-4302 Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ItalySearch for more papers by this authorA. Virdi, A. Virdi Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ItalySearch for more papers by this authorI. Neri, I. Neri Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ItalySearch for more papers by this author M.A. Chessa, M.A. Chessa Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ItalySearch for more papers by this authorF. Filippi, Corresponding Author F. Filippi federicafilippi8@gmail.com orcid.org/0000-0001-8173-4257 Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy Correspondence: F. Filippi. E-mail: federicafilippi8@gmail.comSearch for more papers by this authorA. Patrizi, A. Patrizi orcid.org/0000-0002-8398-0483 Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ItalySearch for more papers by this authorL. Vollono, L. Vollono orcid.org/0000-0001-8858-9531 Dermatology Unit, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, ItalySearch for more papers by this authorA. Sechi, A. Sechi Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ItalySearch for more papers by this authorM. D'Ercole, M. D'Ercole Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ItalySearch for more papers by this authorM. Leuzzi, M. Leuzzi orcid.org/0000-0002-6333-4302 Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ItalySearch for more papers by this authorA. Virdi, A. Virdi Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ItalySearch for more papers by this authorI. Neri, I. Neri Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ItalySearch for more papers by this author First published: 28 April 2020 https://doi.org/10.1111/jdv.16542Citations: 3Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article.Citing Literature Volume34, Issue11November 2020Pages e724-e726 RelatedInformation

INTRODUCTION:Vitiligo is an acquired, idiopathic disorder clinically characterized by amelanotic lesions on the skin which cause significant impairment of patients' quality of life. A variety of treatments have been proposed, with inconsistent results. In the last decades, the use of platelet-rich plasma (PRP) is receiving increasing interest as a potential effective technique in the treatment of several dermatological diseases, including vitiligo.OBJECTIVE:We conducted a review with the aim to identify studies that documented the use of PRP for vitiligo.MATERIALS AND METHODS:Electronic databases of MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) from inception to November 2019 have been searched using different combinations of the following terms: "platelet-rich plasma", "platelet gel", "platelet-rich fibrin", "PRP" and "vitiligo".RESULTS:We identified 6 clinical studies consistent with our research, with a total of 253 patients, listing and discussing the obtained results. In all reports, all treated patients showed a stable vitiligo, and a significantly higher improvement in the PRP groups was always observed compared to control groups. Regarding the side effects, PRP in vitiligo patients is useful and without important side effects.CONCLUSION:PRP is a promising treatment for stable vitiligo lesions in different body sites. The possible use of PRP in combination with traditional therapeutic options and the standardization of processing protocols represents a very fertile field for future research. Larger clinical trials with longer time of observation would provide solid evidence regarding the effectiveness of PRP for the treatment of vitiligo.

Journal of Cutaneous PathologyVolume 48, Issue 4 p. 602-603 NOTES AND COMMENTS Perineural granulomas without neurological manifestations: The great mimicker strikes again Michele Donati, Michele Donati Surgical Pathology, Campus Biomedico University, Rome, ItalySearch for more papers by this authorLaura Vollono, Corresponding Author Laura Vollono laura.vollono@gmail.com orcid.org/0000-0001-8858-9531 Dermatology Unit, Tor Vergata University, Rome, Italy Correspondence Laura Vollono Email: laura.vollono@gmail.com DOI 10.1111/cup.13735Search for more papers by this authorAngela Ferrari, Angela Ferrari Laboratory of Dermatopathology San Gallicano Dermatological Institute IRCCS, Rome, ItalySearch for more papers by this authorAntonella Vulcano, Antonella Vulcano Laboratory of Microbiology, National Institute for Infectious Diseases "L. Spallanzani", Rome, ItalySearch for more papers by this authorPaolo Persichetti, Paolo Persichetti Plastic Surgery, Campus Biomedico University, Rome, ItalySearch for more papers by this authorPietro Donati, Pietro Donati Laboratory of Dermatopathology San Gallicano Dermatological Institute IRCCS, Rome, ItalySearch for more papers by this author Michele Donati, Michele Donati Surgical Pathology, Campus Biomedico University, Rome, ItalySearch for more papers by this authorLaura Vollono, Corresponding Author Laura Vollono laura.vollono@gmail.com orcid.org/0000-0001-8858-9531 Dermatology Unit, Tor Vergata University, Rome, Italy Correspondence Laura Vollono Email: laura.vollono@gmail.com DOI 10.1111/cup.13735Search for more papers by this authorAngela Ferrari, Angela Ferrari Laboratory of Dermatopathology San Gallicano Dermatological Institute IRCCS, Rome, ItalySearch for more papers by this authorAntonella Vulcano, Antonella Vulcano Laboratory of Microbiology, National Institute for Infectious Diseases "L. Spallanzani", Rome, ItalySearch for more papers by this authorPaolo Persichetti, Paolo Persichetti Plastic Surgery, Campus Biomedico University, Rome, ItalySearch for more papers by this authorPietro Donati, Pietro Donati Laboratory of Dermatopathology San Gallicano Dermatological Institute IRCCS, Rome, ItalySearch for more papers by this author First published: 03 May 2020 https://doi.org/10.1111/cup.13735 In response to: “Sarcoidosis with cutaneous perineural granulomas and neurological manifestations: A potential mimicker of leprosy. 1” Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume48, Issue4April 2021Pages 602-603 RelatedInformation

The management and prognosis of squamous cell carcinoma largely depend on its invasiveness and grade of differentiation. Pigmented nail fold squamous cell carcinoma represents a therapeutic challenge, needing careful treatment to preserve nail function. Here, we report the use of dermoscopy and Reflectance Confocal Microscopy to monitor nail fold squamous cell carcinoma in situ and its response to treatment with topical imiquimod.

Photodermatology, Photoimmunology & PhotomedicineVolume 36, Issue 5 p. 408-411 LETTER TO THE EDITOR Good things come to those who wait: Successful response of solar urticaria to omalizumab after 1 year of treatment Laura Vollono, Corresponding Author Laura Vollono laura.vollono@gmail.com orcid.org/0000-0001-8858-9531 Dermatology Unit, University of Rome Tor Vergata, Rome, Italy Correspondence Laura Vollono, MD, Dermatology Unit, Tor Vergata University, Via Cracovia 50, Rome 00133, Italy. Email: laura.vollono@gmail.comSearch for more papers by this authorLuca Bianchi, Luca Bianchi Dermatology Unit, University of Rome Tor Vergata, Rome, ItalySearch for more papers by this authorArianna Piccolo, Arianna Piccolo Dermatology Unit, University of Rome Tor Vergata, Rome, ItalySearch for more papers by this authorSara Mazzilli, Sara Mazzilli Dermatology Unit, University of Rome Tor Vergata, Rome, ItalySearch for more papers by this authorElena Campione, Elena Campione Dermatology Unit, University of Rome Tor Vergata, Rome, ItalySearch for more papers by this authorLaura Diluvio, Laura Diluvio Dermatology Unit, University of Rome Tor Vergata, Rome, ItalySearch for more papers by this author Laura Vollono, Corresponding Author Laura Vollono laura.vollono@gmail.com orcid.org/0000-0001-8858-9531 Dermatology Unit, University of Rome Tor Vergata, Rome, Italy Correspondence Laura Vollono, MD, Dermatology Unit, Tor Vergata University, Via Cracovia 50, Rome 00133, Italy. Email: laura.vollono@gmail.comSearch for more papers by this authorLuca Bianchi, Luca Bianchi Dermatology Unit, University of Rome Tor Vergata, Rome, ItalySearch for more papers by this authorArianna Piccolo, Arianna Piccolo Dermatology Unit, University of Rome Tor Vergata, Rome, ItalySearch for more papers by this authorSara Mazzilli, Sara Mazzilli Dermatology Unit, University of Rome Tor Vergata, Rome, ItalySearch for more papers by this authorElena Campione, Elena Campione Dermatology Unit, University of Rome Tor Vergata, Rome, ItalySearch for more papers by this authorLaura Diluvio, Laura Diluvio Dermatology Unit, University of Rome Tor Vergata, Rome, ItalySearch for more papers by this author First published: 19 May 2020 https://doi.org/10.1111/phpp.12577Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Citing Literature Volume36, Issue5September 2020Pages 408-411 RelatedInformation

Pincer nail is a common condition characterized by excessive transverse nail curvature, progressively pinching the nail bed distally, resulting in cosmetic discomfort, pain and functional limitation. Treatment is difficult and often unsatisfactory. Surgical treatment performed by experienced physicians provides good outcomes. However, patients usually hesitate to undergo invasive procedures, preferring conservative treatments. Unfortunately, these mainly offer only temporary relief and recurrence rate is high. Topical tazarotene has been used in several nail conditions, but its potential remains not fully elucidated. We herewith present a case of pincer nails in a 35-year-old woman successfully treated with tazarotene 0.1% gel applied topically twice a day for 3 months who did not experience recurrence at 1-year follow-up. At 1-year follow-up, no recurrence has been observed. To our knowledge, this is the first case of pincer nails successfully treated with tazarotene 0.1% gel. With our report, we suggest topical tazarotene as a novel, effective conservative treatment of milder cases of this common, albeit disturbing condition. Although our report may not be sufficient to generalize the results, it paves the way for larger studies investigating the potential of this fast, noninvasive therapeutic agent.